The NAME trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic HER2 neg breast cancer

Background: Navebine is an antineplastic agent that has shown afficacy in the treatment of a variety of solid tumors, including breast cancer. The drug can be given intriavenously, but also as oral tablet treatment. Preclinical studies, as well as clinical observations, suggest that the administration of small, frequent doses of chemotherapy (metronomic dosing) has an effect, not only on cancer cells, but also on endothelialcells in the tumor vasculature. By giving smaller, but more frekvent doses of the drug, higher dose intensity, without corresponding side effects, is optained. Whether treatment under the metronomic principle is superior to conventional treatment, has not yet been validated in the clinic, so this study is hoped to clarify this.